Akero Therapeutics/AKRO

$27.30

14.22%
-
1D1W1MYTD1YMAX

About Akero Therapeutics

Akero Therapeutics, Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. The Company’s lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase 2b clinical trials in patients with biopsy-confirmed NASH: a long-term follow-up period for the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), for which it reported results after 24 weeks of treatment, and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Its EFX program focused on patients with cirrhotic NASH (F4, compensated), in Phase 2b clinical trial.

Ticker

AKRO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Andrew Cheng

Employees

51

Headquarters

South san francisco, United States

AKRO Metrics

BasicAdvanced
$1.41B
Market cap
-
P/E ratio
-$2.35
EPS
-0.39
Beta
-
Dividend rate

What the Analysts think about AKRO

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
57.07% upside
High $60.00
Low $33.00
$27.30
Current price
$42.88
Average price target

AKRO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-39.6M
27.74%
Profit margin
0%
-

AKRO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.22%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.49
-$0.55
-$0.60
-$0.71
-
Expected
-$0.80
-$0.67
-$0.63
-$0.68
-$0.86
Surprise
-38.6%
-18.15%
-4.46%
4.22%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Akero Therapeutics stock

Buy or sell Akero Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing